Investing in weight-loss drugs, and why everyone’s talking about student loans
Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
On this episode of the AJ Bell Money & Markets podcast, how financial markets reacted to speculation around the future of Keir Starmer as UK prime minister. [02:00]
Dan Coatsworth and Tom Sieber unpack the latest results from Shell, BP and Barclays. [05:05]
AI has haunted parts of the stock market once again, with financial comparison websites and insurance brokers the latest victims as investors fear major disruption to their business. [11:12]
There was some remarkable news in the pharmaceutical space as Novo Nordisk battled Him & Her’s amid controversy around the launch of copycat weight-loss drugs. The pod team explore the weight loss drug space in more detail and explain why one analyst thinks Greggs is a major loser as people slim down. [15:05]
Dan talks to Trevor Polishchuk from Worldwide Healthcare about how Eli Lilly has scored the top slot in the weight-loss drug market [24:13]. Martin Gamble chats to Oliver Kenyon from RTW Investment about other names to watch in this space. [30:13]
Charlene Young is on the show to explain why everyone’s talking about student loans. [33:00]
Finally, Danni Hewson talks to Pathos Communications about its experiences of listing on the UK stock market and the use of AI in the public relations industry. [45:32]